ReviewKidney international reports2026
Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.
Review in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucodependence in Cardiorenometabolic Disease: Naming the Problem.Kidney international reports · 2026Article
- Response to the letter to the editor entitled "Glucodependence in Cardiorenometabolic Disease: Naming the Problem".Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) remains a major complication of diabetes mellitus and a leading driver of end-stage kidney disease (ESKD), cardiovascular morbidity, and premature mortality worldwide. Despite significant advances in the management of CKD, substantial residual cardiorenal risk persists in patients with diabetes mellitus (DM). The need for additional therapies that target complementary pathophysiological pathways is therefore critical. This review highlights novel and emerging therapeutic strategies with the potential to further reduce the progression of CKD in patients with diabetes mellitus. We explore the clinical rationale and growing body of evidence supporting the use of multitargeting incretin-based therapies which may provide added metabolic and kidney benefits. We also examine the anti-inflammatory, hemodynamic, and antifibrotic effects of aldosterone synthase inhibitors and endothelin receptor antagonists (ERA), which target key pathways involved in progressive kidney injury. In addition, we discuss soluble guanylate cyclase agonists, which modulate the nitric oxide (NO) signaling pathway to improve kidney perfusion and reduce albuminuria, as well as emerging therapies, such as kidney autologous cell therapy and anti-inflammatory agents targeting cytokine and inflammasome pathways. Importantly, we consider patients with type 1 diabetes mellitus (T1D) and the real-world challenges of translating these advances into practice by addressing economic and access-related barriers that continue to shape treatment uptake and equity in care. Together, these agents represent a promising evolution in the treatment of CKD in diabetes mellitus, with the potential to complement existing therapies and address key mechanisms of disease progression. Ongoing and future clinical trials will help define their role in reshaping the standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.